Key result
Semaglutide improves symptoms, exercise function, and weight loss versus placebo in HFpEF.
Why the study?
Does semaglutide (2.4 mg) improve symptoms, physical limitations, exercise function, and weight loss in patients with heart failure with preserved ejection fraction and obesity?
Does semaglutide (2.4 mg) improve symptoms, physical limitations, exercise function, and weight loss in patients with heart failure with preserved ejection fraction and obesity?
In patients with HFpEF and obesity, semaglutide 2.4 mg significantly improves heart failure symptoms, physical limitations, and exercise function while promoting weight loss.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Just for a matter of perspective, [if] people who have a KCCQ-CSS improvement of 15 points or greater, it's a truly transformational change in their symptoms and physical limitations.”
“Collectively, these findings signify an initial paradigm-shifting step toward positioning semaglutide, and possibly other emerging incretin-based therapeutics and weight/metabolism-oriented approaches at the center of obesity-related HFpEF management strategies.”
“The higher BMI, increased hsCRP, lower KCCQ scores, and shorter 6MWD at baseline emphasize excess adiposity, inflammation, symptoms and functional limitations, and reduced exercise function as especially important (but historically overlooked) therapeutic targets.”
Supports semaglutide for symptom relief and weight loss in obese HFpEF; extends prior obesity-trial benefits to this population.
In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
No takes yet. Share an insight, caveat, or question.
Kosiborod et al. (2023) studied this question. Semaglutide improved symptoms, physical limitations, exercise function, and caused greater weight loss compared to placebo in heart failure patients with preserved ejection frac.
Synapse has enriched 10 related papers. Consider them for comparative context: